Adcendo's ADCE-T02, a first-in-class Topoisomerase I inhibitor-based antibody-drug conjugate targeting tissue factor, receives FDA clearance to begin Phase I trials in advanced solid tumors.
Antibody-drug conjugates (ADCs) combine monoclonal antibody specificity with potent small molecule cytotoxicity, precisely delivering toxins to tumors and sparing normal tissues.
The FDA issued a CRL for Atara Biotherapeutics' tabelecleucel due to third-party manufacturing issues, not efficacy or safety data, delaying potential approval for EBV+ PTLD.
Drug Development Updates
Stay informed with timely notifications on clinical trials and research advancements.